康宁克通对增生性瘢痕Ⅰ,Ⅲ型胶原蛋白及前胶原基因原？…

目的 探讨康宁克通在活体中对增生性瘢痕Ⅰ、Ⅲ型胶原合成及降解影响的机理。方法 用免疫组织化学及分子生物学技术，对６例增生性瘢痕局部注射康宁克通３及７ｄ后，Ⅰ、Ⅲ型胶原蛋白及相应前胶原ｍＲＮＡ的原位表达进行了研究。结果 （１）注射７ｄ后，１型胶原蛋白量降低（Ｐ〈０．０５），Ⅲ型胶原蛋白量未见明显降低（Ｐ〉０．０５），而Ⅰ、Ⅲ型前胶原ｍＲＮＡ在注射后３ｄ已被明显抑制（Ｐ〈０．０１），至注射后７ｄ，表达

Study on type I and type III procollagen mRNA and in situ collagen proteins expressions in hypertrophic scars after intralesional Kenalog treatment]

OBJECTIVE: This is to investigate the mechanism of effects of Kenalog on type I and III collagen syntheses and degradation in hypertrophic scars. METHODS: Intralesional injection of Kenalog was performed on 6 patients with hypertrophic scars. On the 3rd day and 7th day after the treatment, 6 samples from the 6 patients each were collected and type I and III collagen proteins and in situ procollagen mRNA expressions were studied by means of immunohistochemistry and molecular biology. RESULTS: On the 7th day after intralesional injection of Kenalog, type I collagen proteins reduced (P < 0.05) and type III collagen proteins did not reduced significantly (P > 0.05). On the 3rd day after intralesional injection of Kenalog, both type I and type III procollagen mRNA expressions were significantly inhibited and on the 7th day both procollagen mRNA expressions decreased further. CONCLUSIONS: Intralesional Kenalog may inhibit type I procollagen mRNA expression more than type III. Gene expressive intensions of type I and III procollagen were higher in hypertrophic scars than in normal skin.